SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Tesla, Inc. engages in the design, development, manufacture, and sale of electric vehicles and energy generation and storage systems. It operates through the Automotive and Energy Generation and Storage segments. The Automotive segment includes the design, development, manufacture, sale, and lease of electric vehicles as well as sales of automotive regulatory credits. The Energy Generation and Storage segment is involved in the design, manufacture, installation, sale, and lease of solar energy generation, energy storage products, and related services and sales of solar energy systems incentives. The company was founded by Jeffrey B. Straubel, Elon Reeve Musk, Martin Eberhard, and Marc Tarpenning on July 1, 2003 and is headquartered in Austin, TX.

Tesla Inc

Tesla hits new all-time highs, fueling community debate around the stock's valuation and future prospects, especially regarding robotaxis. Discussions also cover regulatory issues, with California potentially suspending sales over self-driving claims, though implementation is delayed. Despite mixed news, optimism persists as some anticipate further gains, while others remain cautious due to the stock's high valuation.

BlackRock Institutional Trust Company N.A. - iShares Silver Trust

iShares Silver Trust

SLV is trending as silver prices reach new all-time highs, fueled by supply concerns and increased industrial demand, particularly for AI data centers. The community is discussing whether this rally is sustainable, with some pointing to historical manipulation and potential pullbacks, while others remain bullish, citing a possible shift in wealth away from crypto and into precious metals. Concerns around a potential China-driven supply squeeze are also circulating.

Advisorshares Trust - AdvisorShares Pure US Cannabis ETF

AdvisorShares Pure US Cannabis ETF

MSOS is trending as anticipation builds around potential cannabis rescheduling following reports of Trump's interest in an executive order. Community discussions are focused on potential catalysts like the removal of 280E tax and uplisting, with many expecting significant gains if rescheduling occurs. The ETF's price action reflects optimism, and some are suggesting potential targets and levels to watch.

Navitas Semiconductor Corp. engages in the development of ultra-efficient gallium nitride (GaN) semiconductors. Its GaN power ICs integrate GaN power with drive, control and protection to enable charging, power density, and energy savings for mobile, consumer, enterprise, eMobility and new energy markets. The company was founded by Daniel Kinzer, Nick Fichtenbaum, Gene Sheridan, and Jason Zhang on August 12, 2020 and is headquartered in Torrance, CA.

Navitas Semiconductor Corp

NVTS is trending as investors discuss its recent overnight gains and potential short squeeze, while also noting insider selling and low trading volume. The community is analyzing the company's growth potential in the semiconductor sector, particularly its partnerships related to AI and data centers. Some traders are speculating on possible news or a breakout, while others remain cautious due to recent price drops and market conditions.

AMC Robotics Corp. engages in developing and deploying AI-enabled robotics and smart security solutions, especially for warehouse automation, enterprise security, robotics patrol/incident-response and logistics automation. The company is headquartered in New York, NY.

AMC Robotics Corp.

AMCI is trending as retail investors discuss its potential in the robotics sector following its recent merger and Nasdaq debut. Community members are drawing comparisons to previous high-flying stocks, with some setting ambitious price targets. The stock's volatility and potential short squeeze are also prominent discussion points.

Tilray Brands, Inc. engages as a consumer packaged goods company, which focuses on medical cannabis research and the cultivation, processing, and distribution of cannabis products worldwide. It operates through the followings segments: Cannabis, Distribution, Beverage, and Wellness. The Cannabis segment focuses on cultivation, production, distribution, and sale of both medical and adult-use cannabis products. The Distribution segment is involved in purchase, resale, and distribution of pharmaceutical and wellness products. The Beverage segment refers to the production, marketing, and sale of beverages. The Wellness segment represents the production, marketing, and distribution of hemp-based food and other wellness products. The company was founded on January 24, 2018 and is headquartered in Leamington, Canada.

Tilray Brands Inc

Tilray is surging amid growing anticipation of potential cannabis rescheduling, fueled by news outlets reporting on expected action. Community discussions revolve around potential price targets and short squeezes, with many believing rescheduling would be a game-changer for the industry. As a major player in the cannabis sector, TLRY stands to benefit significantly from any positive regulatory developments.

DBV Technologies SA is a clinical-stage biopharmaceutical company, which engages in the research and development of epicutaneous immunotherapy products. The firm focuses on the development of Viaskin, an electrostatic patch, which may offer a convenient, self-administered, and non-invasive immunotherapy to patients. It also designs a robust clinical development program that includes ongoing clinical trials of Viaskin peanut, and Viaskin milk, as well as pre-clinical development of Viaskin egg. The company was founded by Pierre-Henri Benhamou, Stéphane Benhamou, Bertrand Dupont, Christophe Dupont, and Pierre-Yves Vannerom on March 29, 2002 and is headquartered in Chatillon, France.

DBV Technologies - ADR

DBV Technologies

DBV Technologies ($DBVT) is trending due to positive Phase 3 trial results for its VIASKIN Peanut patch, showing significant desensitization in peanut-allergic children, potentially paving the way for FDA filing. The community is discussing the strong after-hours surge, potential squeeze, and the clinical meaningfulness of the study's desensitization levels. DBVT focuses on immunotherapy via skin patch technology targeting food allergies.

The Children's Place, Inc. engages in the provision of apparel, footwear, accessories, and other items for children. The firm also designs contracts to manufacture and sell fashionable and value-priced merchandise under the brand names of The Children’s Place, Baby Place, and Gymboree. It operates through The Children’s Place U.S. and The Children’s Place International segments. The Children’s Place U.S. segment refers to the company’s U.S. and Puerto Rico-based stores and revenue from its U.S. based wholesale business. The Children’s Place International segment is involved in the Canadian-based stores, revenue from the company’s Canadian-based wholesale business, as well as revenue from international franchisees. The company was founded by David Pulver and Clinton A. Clark in 1969 and is headquartered in Secaucus, NJ.

Childrens Place Inc

Shares of Childrens Place are trending, driven by a closed $450M refinancing deal and increased transformation savings estimates, although Q3 results revealed decreased net sales and a net loss. The community is actively discussing the potential for a short squeeze given the high short interest and low float, along with the company's overall turnaround prospects. Some traders believe PLCE is undervalued with catalysts that could propel a significant upward move, while others express concerns about declining financials.

Affirm Holdings, Inc. operates a platform for digital and mobile-first commerce. Its platform consists of three core elements: a point-of-sale payment solution for consumers, merchant commerce solutions, and a consumer-focused app. The company was founded by Max R. Levchin in 2012 and is headquartered in San Francisco, CA.

Affirm Holdings Inc - Ordinary Shares - Class A

Affirm Holdings Inc

Affirm ($AFRM) is trending after extending its partnership with Amazon for another 5 years, a deal the CFO touts as a win-win. Community members are actively discussing the potential impact of this extended partnership on Affirm's growth, as well as debating the company's valuation and future prospects in the competitive BNPL sector. Some traders point to technical indicators suggesting a bullish outlook, while others remain cautious due to the stock's volatility.

Warner Bros. Discovery, Inc. is a premier global media and entertainment company, which engages in the provision of a differentiated portfolio of content, brands, and franchises across television, film, streaming, and gaming. It operates through the following segments: Studios, Networks, Direct-to-Consumer (DTC), and Corporate. The Studios segment includes producing and releasing feature films for initial exhibition in theaters, producing and initial licensing television programs to networks services as well as third parties, distributing films and television programs to various third party, internal television, and streaming services, distribution through the home entertainment market related consumer products, and themed experience licensing and interactive gaming. The Networks segment focuses on domestic and international television networks. The DTC segment is involved in premium pay-television and streaming services. The company was founded on June 17, 1985 and is headquartered in New York, NY.

Warner Bros. Discovery Inc - Ordinary Shares - Class A

Warner Bros Discovery Inc

WBD is trending amid speculation of a bidding war between NFLX and PSKY, with community members closely watching for the next offer and discussing potential outcomes for shareholders.  The community is weighing the pros and cons of each deal, considering factors like financing, regulatory hurdles, and long-term value. Some investors express concerns about potential overvaluation and debt, while others remain bullish, anticipating a higher bid.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>VIASKIN patch is designed to introduce microgram amounts of an allergen like peanuts to the immune system through intact skin to induce tolerance.</li><li>The company now plans to submit an application to the U.S. Food and Drug Administration seeking approval for Viaskin Peanut in the first half of 2026.</li><li>The company expects its application might be provided a priority review.</li></ul>DBV Technologies (DBVT) said on Tuesday that its late-stage trial evaluating Viaskin Peanut patch for the treatment of peanut allergy in children resulted in significant drop in sensitivity, causing the stock to soar 63% after hours.The company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://dbv-technologies.com/press_releases/dbv-technologies-announces-positive-topline-results-from-phase-3-vitesse-trial-of-viaskin-peanut-patch-in-peanut-allergic-children-aged-4-7-years/">said</a> that the patch demonstrated a statistically significant treatment effect in children aged 4 to 7 years with 46.6% of children in the VIASKIN Peanut arm meeting the treatment responder criteria after 12 months as compared to just 14.8% children who received placebo. The trial enrolled 654 children, more than the target enrollment of 600, who were then randomised to receive the patch or a placebo.According to David Fleischer, global principal investigator of the study, the levels of desensitization achieved in the study after one year of treatment are “highly clinically meaningful and represent substantial progress towards a well-tolerated, non-invasive potential option.”<h2 class="st-heading-2">Safety Results</h2>Safety results were also consistent with the profile observed in previous trials, the company said.Discontinuations due to adverse effects was 3.2% in patients who received the Viaskin Peanut patch as compared to 0.5% in the placebo arm, it added. While two children expected treatment-related serious adverse events and treatment-related anaphylaxis, they continued treatment, the company said. &nbsp;<h2 class="st-heading-2">Looking Forward</h2>The France-headquartered company, which seeks to develop treatment options for food allergies, now plans to submit an application to the U.S. Food and Drug Administration seeking approval for Viaskin Peanut in the first half of 2026.The company expects its application might be provided a priority review, provided that Viaskin Peanut patch was granted Breakthrough Therapy Designation by the FDA.VIASKIN patch is designed to introduce microgram amounts of an allergen like peanuts to the immune system through intact skin to induce tolerance. The company is also studying the patch in peanut allergic toddlers of 1 through 3 years of age and expects to seek approval for the patch in the age group in the second half of 2026 upon completion of trials.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around DBVT stayed within the ‘extremely bullish’ territory over the past 24 hours while message volume stayed at ‘extremely high’ levels.A Stocktwits user highlighted a huge market opportunity, citing the large number of people who are allergic to nuts.<stembedurl>https://www.stocktwits.com/Mushichka/message/639370968</stembedurl>Another sees the stock flying to the moon. “Must be mad crackers if you are even considering shorting this,” they added.<stembedurl>https://www.stocktwits.com/ghcb1981/message/639370886</stembedurl><a href="https://stocktwits.com/symbol/DBVT">DBVT stock</a> has multiplied by about 6 times this year.&nbsp;Also See: <a href="https://stocktwits.com/news-articles/markets/equity/tesla-hits-all-time-high-on-robotaxi-optimism-europe-battery-plans-add-tailwind/cLeJnpgREpg">Tesla Hits All-Time High On Robotaxi Optimism As Wall Street Sees Path To $3T Valuation — Europe Battery Plans Add Tailwind</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

In this photo illustration, the DBV Technologies logo is displayed on the screen of a tablet. (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)

DBV Technologies Stock Soars 63% After Hours As Strong Results For Peanut Allergy Patch Clears Path For FDA Filing

According to David Fleischer, global principal investigator of the study, the levels of desensitization achieved in the study after one year of treatment are “highly clinically meaningful.”

Equity

According to David Fleischer, global principal investigator of the study, the levels of desensitization achieved in the study after one year of treatment are “highly clinically meaningful.”


DBV Technologies (NASDAQ:DBVT) Shares Gap Down - Time to Sell?

DBV Technologies (NASDAQ:DBVT) Shares Gap Down - Here's What Happened...

DBV Technologies (NASDAQ:DBVT) Shares Gap Up - What's Next?

DBV Technologies (NASDAQ:DBVT) Shares Gap Up - Should You Buy...

DBV Technologies (NASDAQ:DBVT) Shares Gap Up - Should You Buy?

DBV Technologies (NASDAQ:DBVT) Reaches New 1-Year High - Still a Buy?

DBV Technologies (NASDAQ:DBVT) Sets New 1-Year High - Here's Why...

Vivo Capital LLC Takes Position in DBV Technologies S.A. $DBVT

Vivo Capital LLC bought a new position in shares of DBV Technologies S.A. (NASDAQ:DBVT - Free Report) during the second quarter, according to its most recent Form 13F filing with the Securities and...

DBV Technologies (NASDAQ:DBVT) Stock Price Up 7.9% - Should You Buy?

DBV Technologies (NASDAQ:DBVT) Trading Up 7.9% - Here's What Happened...

DBV Technologies (NASDAQ:DBVT) Shares Gap Up - Time to Buy?

DBV Technologies (NASDAQ:DBVT) Shares Gap Up - Here's Why...

DBV Technologies (NASDAQ:DBVT) Upgraded at Wall Street Zen

Wall Street Zen raised DBV Technologies from a "sell" rating to a "hold" rating in a report on Friday...

DBV Technologies S.A. (NASDAQ:DBVT) Given Consensus Recommendation of "Hold" by Brokerages

Shares of DBV Technologies S.A. (NASDAQ:DBVT - Get Free Report) have been assigned a consensus rating of "Hold" from the seven ratings firms that are presently covering the company, Marketbeat...

Up more than 2%

Up 0–2%

Flat to down 2%

Down more than 2%

The S&P 500 is modestly lower so far in December, putting the Santa Claus rally in question. The Santa Claus rally refers to the market’s tendency to rise in the final weeks of the year—what do you expect from December 16 through December 31?

What do you expect the S&amp;P 500’s total return to be in the second half of December?

Stocktwits

What do you expect the S&P 500’s total return to be in the second half of December?

Stocktwits Polls

The company announced overwhelmingly positive Phase 3 results for its Viaskin peanut allergy patch, achieving highly clinically meaningful desensitization in children.

Shares exploded over 60-70% in after-hours trading driven by the strong clinical trial results, sparking discussion of continued momentum and price targets.

DBVT
DBV Technologies

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest DBVT News

DBVTDBV Technologies